Key facts
- It has raised $850K across 1 recorded rounds; the latest was Seed Round ($2.7M) in Feb 2025.
- Maxymune Therapeutics has filed 1 Form D with the SEC, most recently Feb 2025 ($850K sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Maxymune Therapeutics
Funding rounds
1 roundsAbout Maxymune Therapeutics
Developer of novel therapeutics designed to address autoimmune diseases and improve patient outcomes. The company's platform focuses on creating innovative molecules targeting new pathways and enhancing formulations of existing treatments, enabling healthcare professionals for better disease management for patients with autoimmune conditions, while improving adherence and reducing side effects for a more effective treatment experience.
- Sector
- Healthcare
- HQ
- Los Altos, CA, United States
- Founded
- 2022
- Website
- maxymunetx.com/
- Ownership
- Privately Held (backing)
Maxymune Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Maxymune Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Maxymune Therapeutics in its N-PORT filings yet. We sweep new filings monthly.